RNAscope together with BOND-III platform will enable pathologists to access leading applications to support their diagnostics labs. Credit: Michal Jarmoluk / Pixabay.

Leica Biosystems and Bio-Techne have launched the CE-IVD marked RNAscope In Situ Hybridization Detection Kit for automation on the BOND-III platform in Europe.

Bio-Techne’s RNAscope together with Leica’s platform will enable pathologists to access the leading applications to support their diagnostics labs.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The technology improves on traditional ISH methodologies through higher target sensitivity and specificity. It detects RNA expression patterns and localisation at the single-cell level with spatial and morphologic context.

Bio-Techne Diagnostics and Genomics Segment president Kim Kelderman said: “We are excited to expand our Leica partnership with the launch of our CE-IVD marked detection kit in Europe.

“Diagnostic labs will now have access to the fully automated RNAscope technology, providing pathologists with a powerful new tool to evaluate biomarkers involved in cancer, infection and other important human diseases.”

The RNAscope technology is said to be highly sensitive and specific due to its double Z probe design.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It provides an extremely high signal-to-noise ratio of staining in various tissue types and enables diagnostic pathologists to visualise, localise and quantify biomarker expression simultaneously.

Leica Biosystems Advanced Staining and Imaging global vice-president Colin White said: “During these difficult times and the ever-changing world due to Covid-19, we are excited about this innovative product as it delivers the benefit of improved workflow, reduced hands-on time and provides our European pathology partners an additional tool in their IVD toolbox against various diseases.”

Last month, Leica Biosystems received the US Food and Drug Administration’s (FDA) emergency use authorisation (EUA) for its Aperio ImageScope DX Viewer for remote diagnosis of Covid-19.